Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Authors

Haeseong Park, Washington University School of Medicine in St. Louis
et al

Journal

Oncotarget

Publication Date

2016

Volume

7

Issue

41

Inclusive Pages

67521-67531

Document Type

Open Access Publication

Rights and Permissions

Park, H., Garrido-Laguna, I., Naing, A., Fu, S., Falchook, G. S., Piha-Paul, S. A., . . . Janku, F. (2016). Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 7(41), 67521-67531. 10.18632/oncotarget.11750. Copyright: © Park et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Park, Haeseong and et al, "Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy." Oncotarget. 7, 41. 67521-67531. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/6534